Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin’s Lymphoma or Multiple Myeloma

This study is currently recruiting participants.

Verified on May 2011 by Celgene Corporation

Brief Summary The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials.
 

Study Phase

 

Phase I